

WE'RE VACCINATION READY

Below is a brief summary of both mRNA vaccines currently authorized:

	PFIZER	MODERNA
EUA Date	12/11/2020	12/18/2020
Age	≥ 16 years	≥ 18 years
Primary Endpoint - Overall Efficacy	95% effective 7 days after second dose	94.5% effective 14 days after second dose
Primary Endpoint - Subgroup Efficacy	Similar efficacy point estimates across age groups, genders, racial and ethnic groups, and participants with medical comorbidities associated with high risk of severe COVID-19	
Regimen	Two doses 21 days apart (second dose can be given as early as 17 days)	Two doses 28 days apart (second dose can be given as early as 24 days)
Volume	0.3mL	0.5mL
Coadministration with other vaccines	<ul style="list-style-type: none"> A minimum interval of 14 days before or after administration with any other vaccines If mRNA COVID-19 vaccines are inadvertently administered within 14 days of another vaccine, doses do not need to be repeated for either vaccine 	
Adverse Reactions	Reactogenic local and system reactions were generally found to be more severe following the second dose in all age groups, and more frequent in younger participants (<55 y/o for Pfizer, <65 y/o for Moderna)	
Persons with current or prior history of COVID-19 infection	The vaccines are safe for individuals who have previously had COVID-19. Persons with current COVID-19 infection should wait until they have recovered and are out of the quarantine period.	